Cheryl Foster
Payments from drug & device makers
Across 12 payments — averaging $76.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$197
- Phadia US Inc.$180
- Paratek Pharmaceuticals, Inc.$125
- Gilead$123
- Boehringer Ingelheim$123
- Dexcom, Inc.$121
- plus $43 from 1 others
What the payments were for
- Food & beverage$912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $197 |
| Phadia US Inc. | 4 | $180 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Gilead | 1 | $123 |
| Boehringer Ingelheim | 1 | $123 |
| Dexcom, Inc. | 1 | $121 |
| Baxter Healthcare | 2 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$125
- JARDIANCE$123
- Epclusa$123
- DEXCOM G6 TRANSMITTER$121
- RYBELSUS$103
How this compares
$912 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 108 | $75,187 |
| MyrbetriqMirabegron | 54 | $30,724 |
| MultaqDronedarone Hcl | 12 | $10,126 |
| JanuviaSitagliptin Phosphate | 11 | $10,022 |
| Donepezil Hcl | 110 | $4,762 |
| Mirabegron ErMirabegron | 11 | $4,401 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,820 |
| Memantine Hcl | 92 | $3,151 |
| Memantine Hcl ErMemantine Hcl | 16 | $3,044 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,207 |
| Famotidine | 74 | $1,780 |
| Esomeprazole Magnesium | 26 | $1,682 |
| Scopolamine | 11 | $1,601 |
| Sertraline Hcl | 145 | $1,580 |
| Duloxetine Hcl | 24 | $1,560 |
Paid to pharmacies, not to this prescriber.
Other family in Bryan
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.